Gwenn Hansen Nurix Therapeutics, Inc. (NRIX) insider trading activity

Gwenn Hansen is Chief Scientific Officer of Nurix Therapeutics, Inc.. Currently has a direct ownership of 55,937 shares of NRIX, which is worth approximately $646,631. The most recent transaction as insider was on Mar 16, 2021, when has been sold 800 shares (Common Stock) at a price of $45.0 per share, resulting in proceeds of $36,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 55.9K

10.39% 3M change

53.66% 12M change

Total Value Held $646,631

Gwenn Hansen Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 16 2021	SELL Open market or private sale	$36,000 $45.0 p/Share	800 Reduced 5.48%	13,804 Common Stock
Mar 16 2021	BUY Exercise of conversion of derivative security	$5,808 $7.26 p/Share	800 Added 5.19%	14,604 Common Stock
Mar 01 2021	SELL Open market or private sale	$28,760 $35.95 p/Share	800 Reduced 5.48%	13,804 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	$5,808 $7.26 p/Share	800 Added 5.19%	14,604 Common Stock
Feb 18 2021	SELL Open market or private sale	$29,392 $36.74 p/Share	800 Reduced 6.25%	12,000 Common Stock
Feb 18 2021	BUY Exercise of conversion of derivative security	$5,808 $7.26 p/Share	800 Added 5.88%	12,800 Common Stock
Nov 30 2020	BUY Exercise of conversion of derivative security	$10,080 $0.84 p/Share	12,000 Added 50.0%	12,000 Common Stock

Gwenn Hansen

Chief Scientific Officer

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NRIX shares.

Notify only if

Value

Insider Trading

Get notified when an Nurix Therapeutics, Inc. insider buys or sells NRIX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Nurix Therapeutics, Inc.

Track Activities on NRIX

Account